Corcept Therapeutics/$CORT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Ticker
$CORT
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
500
ISIN
US2183521028
Website
CORT Metrics
BasicAdvanced
$7.8B
64.77
$1.14
0.21
-
Price and volume
Market cap
$7.8B
Beta
0.21
52-week high
$117.33
52-week low
$29.42
Average daily volume
1.3M
Financial strength
Current ratio
3.065
Quick ratio
2.688
Long term debt to equity
0.856
Total debt to equity
1
Profitability
EBITDA (TTM)
111.327
Gross margin (TTM)
98.36%
Net profit margin (TTM)
19.55%
Operating margin (TTM)
16.10%
Effective tax rate (TTM)
1.56%
Revenue per employee (TTM)
$1,370,000
Management effectiveness
Return on assets (TTM)
9.18%
Return on equity (TTM)
21.77%
Valuation
Price to earnings (TTM)
64.766
Price to revenue (TTM)
11.179
Price to book
11.48
Price to tangible book (TTM)
11.48
Price to free cash flow (TTM)
43.251
Free cash flow yield (TTM)
2.31%
Free cash flow per share (TTM)
171.07%
Growth
Revenue change (TTM)
30.93%
Earnings per share change (TTM)
8.36%
3-year revenue growth (CAGR)
21.71%
10-year revenue growth (CAGR)
35.75%
3-year earnings per share growth (CAGR)
7.72%
10-year earnings per share growth (CAGR)
17.91%
What the Analysts think about CORT
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
Bulls say / Bears say
Corcept's experimental drug relacorilant, combined with chemotherapy, achieved a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients during a late-stage trial, leading to an 80% surge in the company's shares. (reuters.com)
The company reported a 40% year-over-year increase in revenue for 2024, reaching $675 million, and provided a 2025 revenue guidance of $900–$950 million, indicating strong financial health and growth prospects. (biospace.com)
Analysts have raised their price targets for Corcept, with Truist Securities increasing its target to $76, citing the robust performance of Korlym and the promising pipeline of clinical trials. (investing.com)
Corcept is facing antitrust lawsuits from Teva Pharmaceuticals and several healthcare companies, which could result in significant legal costs and potential penalties. (panabee.com)
The Phase 2 DAZALS trial for dazucorilant in ALS failed to meet its primary endpoint, raising concerns about the efficacy of the drug in this indication. (panabee.com)
A director at Corcept sold 2,200 shares of the company's stock, totaling approximately $149,776, which might be perceived negatively by investors. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CORT Financial Performance
Revenues and expenses
CORT Earnings Performance
Company profitability
CORT News
AllArticlesVideos
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
Business Wire·3 days ago
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
Business Wire·3 weeks ago
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corcept Therapeutics stock?
Corcept Therapeutics (CORT) has a market cap of $7.8B as of June 26, 2025.
What is the P/E ratio for Corcept Therapeutics stock?
The price to earnings (P/E) ratio for Corcept Therapeutics (CORT) stock is 64.77 as of June 26, 2025.
Does Corcept Therapeutics stock pay dividends?
No, Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Corcept Therapeutics dividend payment date?
Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders.
What is the beta indicator for Corcept Therapeutics?
Corcept Therapeutics (CORT) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.